Over the past six decades, anti-thrombotic drug therapies have undergone a revolution, leading to major improvements in ...

The Target-D clinical trial recruited 630 adults with heart disease from April 2017 to May 2023 About 78 percent of ...

A man in the 40s presented with acute vertigo and occipital headache. He was diagnosed with right posterior inferior ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...

If you’re lucky (or unlucky, depending on your perspective), you might spot a timber rattlesnake basking on a sun-warmed rock – one of Minnesota’s few venomous snakes and a protected species in the ...

International study of 29,000 patients shows blood thinner clopidogrel superior to aspirin for heart attack prevention.

Daily steroid pills are often necessary for severe cases of asthma, but they raise the risk of several serious conditions.

Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

A monthly injection has helped 90% of severe asthma patients reduce daily steroid tablets, which are associated with ...

Coronary artery disease is one of the leading causes of morbidity and mortality worldwide. Although it can present with an ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that Eisai has completed the rolling submission of the Supplemental Biologics License Application (sBLA ...